EGFRv3-CAR-T

N/A

Report date: 2025/03/20 14:58:35

Base Information

Drug NameEGFRv3-CAR-T
Drug Alias Nameanti-EGFRvIII CAR T-cell therapy (China Immunotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChina Immunotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChina Immunotech Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A